Retatrutide, a novel dual-acting glucose-responsive incretin mimetic, represents a significant leap in peptide medicines for the handling of type 2 diabetes and, increasingly, weight issues. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor stimulant, offering a more comple